 Financial Times |
AstraZeneca takes option on Prosidion diabetes assets; advances asthma drug
The Pharma Letter Separately, Dynavax Technologies (Nasdaq: DVAX) and AstraZeneca yesterday announced their decision to advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Investigational New Drug-enabling preclinical toxicology studies. … The Market Just Spanked My Stock! |
View full post on asthma – Google News